Avalo Therapeutics (AVTX) Accounts Payables (2014 - 2026)
Avalo Therapeutics (AVTX) posted Accounts Payables of $356000.0 for Q1 2026, up 159.85% on a QoQ basis from $137000.0 in Q4 2025, and down 47.72% year-over-year from $681000.0 in Q1 2025.
Avalo Therapeutics (AVTX) Accounts Payables (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Accounts Payables history runs 13 years deep, the most recent figure standing at $356000.0 for Q1 2026.
- Quarterly Accounts Payables fell 47.72% year-over-year to $356000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $356000.0 (down 47.72% YoY) and the FY2025 annual result came in at $137000.0, down 51.59% from the prior year.
- Accounts Payables was $356000.0 for Q1 2026 at Avalo Therapeutics, up from $137000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $5.6 million in Q1 2023 and bottomed at $137000.0 in Q4 2025.
- A 5-year average of $1.5 million and a median of $789000.0 in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables slumped 84.52% — and 2025, when it jumped 261.77%.
- Avalo Therapeutics' Accounts Payables stood at $2.9 million in 2022, then sank by 84.52% to $446000.0 in 2023, then plunged by 36.55% to $283000.0 in 2024, then plunged by 51.59% to $137000.0 in 2025, then soared by 159.85% to $356000.0 in 2026.
- Business Quant data shows AVTX's Accounts Payables at $356000.0 in Q1 2026, $137000.0 in Q4 2025, and $474000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | 356,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 356,000.00 |
| Dec 31, 2025 | 137,000.00 |
| Sep 30, 2025 | 474,000.00 |
| Jun 30, 2025 | 2.37 Mn |
| Mar 31, 2025 | 681,000.00 |
| Dec 31, 2024 | 283,000.00 |
| Sep 30, 2024 | 1.81 Mn |
| Jun 30, 2024 | 654,000.00 |
| Mar 31, 2024 | 916,000.00 |
| Dec 31, 2023 | 446,000.00 |
| Sep 30, 2023 | 789,000.00 |
| Jun 30, 2023 | 751,000.00 |
| Mar 31, 2023 | 5.57 Mn |
| Dec 31, 2022 | 2.88 Mn |
| Sep 30, 2022 | 1.45 Mn |
| Jun 30, 2022 | 2.16 Mn |
| Mar 31, 2022 | 3.76 Mn |
| Dec 31, 2021 | 3.37 Mn |
| Sep 30, 2021 | 3.57 Mn |
| Jun 30, 2021 | 3.97 Mn |